NCT04900519RecruitingPhase 1
A Phase 1, Open-Label, Dose-Escalation Study of the Safety and Efficacy of STI-6643, an Anti-CD47 Human Monoclonal Antibody, in Subjects With Advanced Solid Tumors
Sorrento Therapeutics, Inc.10 sites in 1 country100 target enrollmentStarted: November 24, 2021Last updated:
Conditions
Trial Snapshot
- Phase
- Phase 1
- Status
- Recruiting
- Sponsor
- Sorrento Therapeutics, Inc.
- Enrollment
- 100
- Locations
- 10
- Primary Endpoint
- Safety of STI-6643
Study Overview
Brief Summary
This is a first-in-human, phase 1, open-label, dose-escalation study of STI-6643 administered by intravenous infusion in subjects with a relapsed/refractory advanced solid tumor.
Detailed Description
This is a first-in-human, phase 1, open-label, dose-escalation study of STI-6643 administered by intravenous infusion in subjects with a relapsed/refractory advanced solid tumor.
The study will determine an MTD and RP2D using a conventional 3+3 study design with priming dose identification (PDI) stage and therapeutic dose (TD) escalation (TDE) stage. Dose limiting toxicity evaluated over the initial 28 days of STI-6643 administration.
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Signed informed consent
- •Age ≥ 18 years
- •ECOG Performance Status ≤ 2
- •Histologically- or cytologically-confirmed solid tumor
- •Patient has relapsed, is refractory to, or intolerant of standard of care therapy
- •No available approved therapy that may provide clinical benefit (per Investigator)
- •Measurable or evaluable disease by RECISTv1.14
- •Life expectancy of > 12 weeks (per Investigator)
- •Adequate laboratory parameters including:
- •Absolute neutrophil count (ANC) ≥ 1500/mm3
- •Platelets ≥ 100,000/mm3
- •Hemoglobin ≥ 12 g/dL (in the absence of transfusion over the prior 2 weeks)
- •AST/SGOT ≤ 2.5 x ULN (≤ 5 x ULN if known liver involvement)
- •ALT/SGPT ≤ 2.5 x ULN (≤ 5 x ULN if known liver involvement)
- •Total bilirubin ≤ 2.0 x ULN (unless diagnosis of Gilbert's syndrome in which case < 3.0 times ULN)
- •Serum creatinine ≤ 2.0 x ULN or estimated GFR ≥ 45 mL/min (per Cockcroft- Gault equation)
- •If residual treatment related toxicity from prior therapy:
- •Treatment related toxicity resolved to ≤ Grade 1 (alopecia excepted), or
- •Treatment related toxicity resolved to ≤ Grade 2 with prior approval of the Medical Monitor
- •Willingness to comply with the study schedule and all study requirements
- •[Females] Must be postmenopausal, surgically sterile, or agree to use adequate contraception (per Investigator) throughout the study and for a least 30 days following the last dose
- •[Males] Must be surgically sterile or must agree to use adequate contraception (per Investigator) throughout the study and for at least 30 days following the last dose
- •[Males] Willingness to refrain from donating sperm throughout the study and for at least 30 days following the last dose
- •[Females] If of child-bearing potential, must have a negative serum pregnancy test
Exclusion Criteria
- •Participating in any other interventional clinical study
- •Previous exposure to an anti-CD47 or SIRPα antibody
- •≤ 28 days (or 5 half-lives if shorter) between of systemic anti-tumor treatment (e.g., chemotherapy, endocrine therapy, immunotherapy, cellular therapy) and the 1st dose of STI-6643
- •≤ 28 days from prior irradiation (≤ 7 days from limited field irradiation for control of symptoms) and the 1st dose of STI-6643
- •≤ 28 days between major surgery (≤ 7 days from minor surgical procedures, no waiting period following central catheter placement)
- •≤ 7 days between administration of G-CSF, GM-CSF, erythropoietin, thrombopoietin or IL11 and the 1st dose of STI-6643
- •≤ 7 days between systemic immunosuppressive therapy in excess of 10 mg/day prednisone equivalent and the 1st dose of STI-6643 (topical or inhaled corticosteroids not restricted)
- •≤ 28 days between a live attenuated vaccine and the 1st dose of STI-6643
- •Known central nervous system (CNS) involvement with tumor (e.g., metastases, meningeal carcinomatosis)
- •Active second malignancy requiring ongoing systemic treatment
- •History of primary immunodeficiency disorders
- •History of active pulmonary tuberculosis
- •History of COVID-19 symptoms unless COVID-19 test negative ≤ 72 hours of the 1st dose of STI-6643
- •≤ 12 weeks from an allogeneic hematopoietic stem cell transplant and C1D1 or active graft-versus-host disease (GvHD)
- •Active infection (e.g., bacterial, viral, fungal) requiring systemic treatment ≤ 72 hours of the 1st dose of STI-6643
- •Known HIV-positive with CD4+ cell counts < 350 cells/uL or a history of an AIDS defining opportunistic infection
- •Known T-cell leukemia virus type 1 (HTLV1) infection, hepatitis B virus (HBV) or hepatitis C virus (HCV) viremia
- •Significant risk for HBV reactivation (defined as HbsAg positive, HbcAb positive or HBV DNA positive)
- •Detectable HCV RNA
- •Pregnant or breast feeding
- •History of clinically significant cardiovascular abnormalities including:
- •Congestive heart failure (NYHA classification ≥ 3) within 6 months of the 1st dose of STI-6643
- •Unstable angina pectoris
- •≤ 6 months from myocardial infarction and the 1st dose of STI-6643
- •Arrhythmias (other than atrial fibrillation) requiring ongoing treatment
- •QTcF interval > 480 msec (using Fridericia's formula)
- •Uncontrolled hypertension (i.e., systolic BP > 180 mmHg or diastolic BP > 100
- •Any condition, including the presence of laboratory abnormalities, that places the subject at an unacceptable risk if the subject was to participate in the study.
Outcomes
Primary Outcomes
Safety of STI-6643
Time Frame: Baseline through study completion at up to approximately 31 months
Safety as assessed by incidence of adverse events, SAEs, DLTs, and clinically significant changes in safety lab results
Secondary Outcomes
- STI-6643 receptor occupancy(Day 1 through Day 22)
- Anti-drug antibodies directed to STI-6643(Day 1 through Day 15)
- PK parameters(Day 1 through Day 22)
- Overall response rate(Day 1 through study completion at up to approximately 31 months)
- Duration of response(Day 1 through study completion at up to approximately 31 months)
Investigators
Study Sites (10)
Loading locations...
Similar Trials
Completed
Phase 1
RU Anti-SARS-CoV-2 (COVID-19) mAbs in Healthy VolunteersCovid19NCT04700163Rockefeller University23
Completed
Phase 1
A Study to Assess Safety and Pharmacokinetics of MOXR0916 in Participants With Locally Advanced or Metastatic Solid TumorsNeoplasmsNCT02219724Genentech, Inc.174
Terminated
Phase 1
Phase 1 Safety and Tolerability Study of Andes-1537 for Injection in Patients With Advanced Unresectable Solid TumorsAdvanced Unresectable Solid TumorsNCT02508441Andes Biotechnologies22
Completed
Phase 1
Pharmacokinetic and Safety Study of MRX-2843 in Adults With Relapsed/Refractory Advanced and/or Metastatic Solid TumorsAdvanced CancerMetastatic CancerNeoplasmsNeoplasm MetastasisNeoplastic ProcessesPathologic ProcessesNCT03510104Meryx, Inc.42
Recruiting
Phase 1
A First-in-human, Clinical Trial Assessing the Safety of ES2B-C001-S01 With or Without [Adjuvant] in Patients With HER2-expressing Metastatic Breast Cancer.Breast CancerNCT06746688ExpreS2ion Biotechnologies40